Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. März 2026 16:30 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
03. März 2026 16:30 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Castle Biosciences will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time.
26. Februar 2026 16:05 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.
19. Februar 2026 17:46 ET | Quelle: Castle Biosciences, Inc.

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Castle announced the publication of a validation study in the Journal of the American Academy of Dermatology for its AdvanceAD-Tx test.
05. Februar 2026 07:00 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...
11. Januar 2026 16:00 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Castle today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025.
19. Dezember 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences announces inducement grants of 139,494 RSUs to 83 new employees under Nasdaq Listing Rule 5635(c)(4).
17. Dezember 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

New data show DecisionDx-UM combined with PRAME provides superior prediction of metastasis and survival in uveal melanoma compared to NGS.
12. Dezember 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Castle announced the publication of a new systematic review and meta-analysis related to its TissueCypher test in the Journal of Clinical Gastroenterology.
09. Dezember 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test.

Nächste Seite